Organic compounds -- part of the class 532-570 series inventions 10/07

20070249823 - Process for preparing gemcitabine and associated intermediates: The present invention provides novel intermediates, which preferably include 3-substituted, alkyl 2,2-difluoro-3-hydroxy-3-(2,2-dialkyldioxolan-4-yl)-propionate derivatives, and 3,5-disubstituted-2-deoxy-2,2-difluoro-1-oxo-D-ribose derivatives. The present invention also provides processes for producing such intermediates and processes for producing gemcitabine therewith.... Agent: Leydig Voit & Mayer, Ltd

20070249824 - Method of manufacturing cellulose acetate, high temperature steam reactor vessel used in the same method, and superheated steam generator used in the same method: The present invention relates to a method of manufacturing cellulose acetate by use of a high temperature steam reactor vessel and a superheated steam generator. According to this method, a material to which solid catalyst added is subject to a steaming process so as to cause cellulose content to be... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070249818 - Method for the preparation of 2'-deoxy-2',2'-difluorocytidine: This invention relates to an improved method for stereoselectively preparing 2¢¥-deoxy-2¢¥,2¢¥-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase of formula (IV) in a solvent to obtain a nucleoside of formula (II) with removing the silyl halide of formula... Agent: Sughrue Mion, PLLC

20070249819 - Sirna targeting wee1 homolog (wee1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070249820 - Activatable ribozymal purification constructs and methods of use: Activatable ribozymal purification constructs are used to rapidly and efficiently purify RNA, including non-denatured RNA. The activatable ribozymal purification construct includes an activatable ribozyme covalently bound to a target RNA moiety. The activatable ribozyme is attached to an immobilizing moiety, which is capable of binding to solid support. Upon activation,... Agent: Paul, Hastings, Janofsky & Walker LLP

20070249821 - Small rna purification: The present invention relates to methods, kits, and compositions for purifying small RNA molecules. In particular, the present invention provides methods for purifying small RNA molecules from a sample containing both small RNA molecules and larger RNA molecules using a compaction agent and a RNA binding matrix, as well as... Agent: Medlen & Carroll, LLP

20070249822 - Photolabile coumarinylmethyl esters of cyclic nucleotides, methods for their preparation and their use: e

20070249825 - Decolorized raw cotton linters and preparation of ether derivatives therefrom: A process for decolorizing cut raw cotton linters (RCL) through the removal of color bodies contained in the cut RCL mass is disclosed as well as a process for using the resultant decolorized RCL in the production of cellulose ether derivatives.... Agent: Hercules Incorporated Hercules Plaza

20070244309 - Organic conductor: The present invention provides an organic conductor comprising a deoxyribonucleic acid (DNA) and an electric charge-donating material bonded to the deoxyribonucleic acid, and an organic conductor comprising at least two DNAs; and an electric charge-transfer substance bonding to each base of the two DNAs.... Agent: Oliff & Berridge, PLC

20070244310 - Polynucleotides for use tags and tag complements, manufacture and use thereof: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described.... Agent: Goodwin Procter LLP Patent Administrator

20070244311 - Sirna targeting coatomer protein complex, subunit beta 2 (cpob2): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070244312 - Sirna targeting phosphoinositide-3-kinase, class 2, alpha polypeptide (pik3c2a): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070244313 - Method for detecting base mutation: The present invention relates to methods for precisely and effectively detecting mutations of organism.... Agent: Jones Day

20070244314 - Method for extracting nucleic acid and nucleic acid-extracting apparatus: A method for extracting nucleic acid comprising: adsorbing nucleic acid to a nucleic acid-adsorptive solid carrier by contacting a sample solution containing nucleic acid with the nucleic acid-adsorptive solid carrier; washing the nucleic acid-adsorptive solid carrier by contacting a washing solution with the nucleic acid-adsorptive solid carrier, while the nucleic... Agent: Birch Stewart Kolasch & Birch

20070238865 - 1-alpha-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof: 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) having the 3-hydroxy group protected with a biphenylcarbonyl group is a solid which can be easily purified by a simple procedure such as recrystallization, and therefore, it can be advantageously used as an intermediate in the preparation of gemcitabine in a large scale. Further, the... Agent: Sughrue Mion, PLLC

20070238866 - Methods of producing c-aryl glucoside sglt2 inhibitors: Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070238867 - Method for manufacturing water soluble chitosan having granular particles: A method for manufacturing water-soluble chitosan with granular particles (20˜40 mesh) makes chitin dissolve into the acid water. Put chitin into the water, by mixing or an adequate vibration, and the water-soluble chitosan is produced. Further, it has excellent preservative and stable properties.... Agent: Hdsl

20070238868 - Sirna targeting chemokine (c-x-c motif) receptor 4 (cxcr4): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070238869 - Cdr-grafted anti-tissue factor antibodies and methods of uses there of: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also... Agent: Philip S. Johnson Johnson & Johnson

20070238870 - Hybridization device and hybridization method: The hybridization device of the invention aims to attain a hybridization reaction of high reproducibility. A hybridization device 2 for a hybridization reaction of nucleic acid has a cover member 10 that defines a cavity 12, which includes a nucleic acid fixation area 6 of a substrate 4 for fixation... Agent: Burr & Brown

20070238871 - Glycolipids and analogues thereof as antigens for nkt cells: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070238872 - Processes for chemical synthesis of lipochitooligosaccharides: Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the phthaloyl group, a fatty acid may be added on the terminal glucosamine unit, forming a lipochitooligosaccharide. The processes... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070232796 - Medical solution, a method for producing said medical solution and use thereof: The present invention relates to a medical solution comprising a first single solution containing glucose and/or glucose-like compound. According to the present invention said first single solution has a pH in the range of 1.8-2.6. The present invention further relates to a method for producing said medical solution as well... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070232797 - Sirna targeting cell division cycle 2-like 5(cdc2l5): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070232798 - Process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom: Oligonucleotide analogs are disclosed having pyrimidine monomeric sub-units therein that are modified at the 2′ and 5′ positions. Monomeric sub-units having these modifications may be further modified at the 2′ position. Improved processes for the synthesis of 2′-O-substituted pyrimidine nucleosides are also provided. The processes feature alkylation of a 2,2′-anhydropyrimidine... Agent: Woodcock Washburn LLP